Danish specialty pharmaceutical company H Lundbeck A/S (OTCPK:HLUYY)
(LUN.CO) is facing down some steep patent cliffs, as about two-thirds
of the company's first revenue loses patent protection over the next two
and a half years. Management hopes that significant new drugs launched
with partners Takeda (OTCPK:TKPYY) and Otsuka (OTCPK:OTSKY)
will more than fill the gap, and some recent updates on key drug
Brintellix have been positive. Lundbeck is also looking at upside
potential from desmoteplase, brexpiprazole, and Northera (which Lundbeck
is acquiring in its announced deal for Chelsea Therapeutics (CHTP)),
though these are higher-risk options today. All told, while Lundbeck
remains a risky proposition, there is still upside to over $30.
Follow this link for more:
Lundbeck Delivers Some Data-Driven Upside
No comments:
Post a Comment